Moderna sees FY26 revenue growth up to 10%

The company said, “Moderna (MRNA) expects up to 10% revenue growth in 2026, driven by the annualized impact of its long-term partnerships with the UK, Canada and Australia and continued strong uptake of mNEXSPIKE in the U.S. and launches in other countries. In addition, the Company has multiple growth opportunities in 2027 and beyond. The Company is reducing its 2026 and 2027 expected cash costs to approximately $4.2B and a range of $3.5B to $3.9B, respectively. Moderna will achieve this through disciplined cost management and R&D prioritization, while manufacturing improvements are projected to improve gross margins by more than 10 percentage points over the next three years. Moderna is increasing its R&D investment allocation in oncology and rare diseases as large infectious disease investments conclude. The Company’s balance sheet sufficiently funds its investments through targeted cash breakeven in 2028. Moderna announced it has closed a five-year term loan facility for up to $1.5B of capital from Ares Management Credit Funds. The non-dilutive financing bolsters the Company’s strong balance sheet and provides increased flexibility. Moderna remains confident in its strong financial framework with enhanced liquidity and today updated its 2025 projected year-end cash and investment balance to a range of $7.1B to $7.6B, tied to the $0.6B initial loan draw and increased from previous expectations of $6.5B to $7B.”